The firm outdid even that total thanks to backing from investors including the European Investment Fund, which doubled its initial €30m commitment to become the fund’s largest backer at 27.7%. Ysios is tapping Fund III to invest in companies developing disruptive therapeutic products and platform technologies, backing seed, early stage and development-stage businesses “at the forefront of the future of medicine”. About 80% of the YBF 3 investments will target Europe, with a special focus on Spain, while the remainder of the fund will target opportunities in North America. More than 60% of the portfolio has already been constructed, Ysios said, with eight investments made in the last 12 months by blue-chip European and US investors.